Excision BioTherapeutics
PrivateLast Round
Grant
Sep 29, 2022
Total Funding Raised
$76.85M
Company Overview
Excision BioTherapeutics operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Grant round in September 2022.
Excision BioTherapeutics is a biotechnology company developing CRISPR-based gene editing therapeutics to cure viral infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Excision BioTherapeutics Comparables
Compare Excision BioTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PROVIREX Genome Editing Therapies GmbH | 88% | |
| American Gene Technologies | 84% | |
| Exavir Therapeutics | 78% |
For institutional investors. Book with your work email.
Excision BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 29, 2022 | ||||
| Series A | Feb 17, 2021 | ||||
| Seed | Sep 6, 2017 |
For institutional investors. Book with your work email.
Excision BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series A |
| Cota Capital | Series A |
| Gaingels | Series A |
| GreatPoint Ventures | Series A |
| WRVI Capital | Series A |
| ARTIS Ventures | Series A, Seed |
| Bioverge | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 17, 2025
Presented data at the ICE-HBV Hepatitis B Cure Symposium.
- Sep 17, 2025
EBT-107 program shows safety and potency for hepatitis B treatment.
For institutional investors. Book with your work email.
Excision BioTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Excision BioTherapeutics's valuation, stock price, and market status.
Is Excision BioTherapeutics a public or private company?
Excision BioTherapeutics is a private company.
What is the current stock price of Excision BioTherapeutics?
Excision BioTherapeutics is a private company, so its shares have no public market price. Caplight tracks Excision BioTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Excision BioTherapeutics worth (valuation)?
Valuation information for Excision BioTherapeutics is not publicly available.
Can I buy Excision BioTherapeutics stock?
Excision BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Excision BioTherapeutics's last funding round?
Excision BioTherapeutics's most recent funding round was Grant on September 29, 2022.
Who are the main investors in Excision BioTherapeutics?
Key investors in Excision BioTherapeutics include GreatPoint Ventures, GreatPoint Ventures, WRVI Capital, ARTIS Ventures.
Will Excision BioTherapeutics IPO soon?
No public IPO plans have been announced for Excision BioTherapeutics.
How can I track Excision BioTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Excision BioTherapeutics's shares on secondary markets.